by Medicine by Design | Aug 6, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Mark Curtis | Jun 25, 2014
. Welcome to your regenerative medicine deal review for the month of May. The space was quiet this past month; however, NeoStem did strike up a licensing deal with China-based Cellular Biomedicine Group to provide international reach to its newly acquired targeted...
by Mark Curtis | Mar 11, 2014
. Welcome to your update from the clinic for the month of February! OncoMed is the leader in news this month with various Phase 1b trials for its cancer stem cell-targeting fusion protein. Immunocellular Therapeutics and StemCells Inc. file orphan drug designations...
by Angela C. H. McDonald | Aug 13, 2012
It takes precision, focus and persistence to perfect the art of origami. So perhaps it is no accident that researchers have needed to apply the same skills to overcome challenges in siRNA delivery, right down to the folding. A couple of years ago, my fellow blogger...
by Ben Paylor | Aug 10, 2011
Did I request thee, Maker, from my clay To mould me man? Did I solicit thee From darkness to promote me? – Paradise Lost, Milton This harrowing quote from Milton, if framed as a first-person narrative of a stem cell’s fate, paints a troubling (and highly...
Comments